EUVIMEDEUVIMED entdecken
Systematische ÜbersichtMetaanalyse

Streptozotocin-based chemotherapy in advanced PanNETs: a systematic review and meta-analysis

Streptozotocin-basierte Chemotherapie bei fortgeschrittenen PanNETs: systematische Übersicht und Metaanalyse

Giulia Arrivi, Giuseppe Lamberti iD, Sara Pusceddu, Riccardo Marconcini, Maria Grazia Maratta iD, Francesco Panzuto, Davide Campana iD

Endocrine-Related Cancer · 01.11.2026 · 33 (11)

DOI: 10.1530/erc-26-0338 ↗

Auf einen Blick

Die Übersichtsarbeit zeigt bei fortgeschrittenen PanNETs unter STZ-haltigen Regimen eine ORR von 36,1 %. Die 12- und 24-Monats-PFS-Benchmarks waren 59,2 % bzw. 41,5 %.

Fragestellung

Wie hoch sind objektive Ansprechrate und landmark-PFS unter STZ-haltigen Regimen bei fortgeschrittenen PanNETs?

Methode

Systematische Übersicht und Metaanalyse von randomisierten Studien, prospektiven Studien und retrospektiven Kohorten; ELIGIBLE- und ALL-Dataset; Random-effects-Analysen.

Ergebnisse

27 Studien mit 1.744 Patient:innen. Im ELIGIBLE-Dataset: ORR 36,1 % (95 %-KI 30,6–42,0; 95% prediction interval 23,0–51,0). Landmark-PFS: 59,2 % nach 12 Monaten und 41,5 % nach 24 Monaten.

Einschränkungen

ALL-Dataset heterogener; keine statistisch signifikanten Unterschiede zwischen Regimenfamilien; Evidenz sehr niedrig wegen Bias und Inkonsistenz.

Schlussfolgerung der Autor:innen

In Kohorten mit standardisierter Outcome-Erfassung waren STZ-haltige Regime bei etwa einem Drittel der Patient:innen mit objektivem Ansprechen verbunden.

Kernaussagen

  • ORR im ELIGIBLE-Dataset: 36,1 %
  • Landmark-PFS: 59,2 % nach 12 Monaten, 41,5 % nach 24 Monaten
  • Evidenz sehr niedrig; keine Unterschiede zwischen Regimenfamilien

Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.

Kurz gefasst

Systematische Übersicht in der Zeitschrift Endocrine-Related Cancer, online erschienen am 19.10.2026. Verfasst von Giulia Arrivi und 6 weiteren Autor:innen. Beteiligte Einrichtung: Oncology Unit, Department of Clinical and Molecular Medicine, Sant'Andrea University Hospital, Sapienza University of Rome , Rome, Italy. Hauptthemen laut MEDLINE: Neuroendocrine Tumors, Pancreatic Neoplasms, Streptozocin. Die Arbeit nennt 36 Literaturangaben.

Auf einen BlickAbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Streptozotocin (STZ)-based chemotherapy remains a treatment option for advanced pancreatic neuroendocrine tumours (PanNETs), particularly when tumour shrinkage is a therapeutic priority. However, its activity has been reported across heterogeneous treatment schedules, patient populations, and response-assessment eras. We conducted a systematic review and meta-analysis to estimate objective response rate (ORR) and landmark progression-free survival (PFS). We systematically reviewed randomised trials, prospective studies, and retrospective cohorts reporting ORR and/or PFS with STZ-containing regimens. Random-effects meta-analyses were conducted in a primary ELIGIBLE dataset restricted to advanced or metastatic pancreatic-only cohorts with standardised outcome assessment, and in a broader ALL dataset for contextual analyses. Comparisons across regimen families were exploratory. Twenty-seven studies including 1,744 patients were included. In the ELIGIBLE dataset, pooled ORR was 36.1% (95% CI: 30.6–42.0), with a 95% prediction interval of 23.0–51.0%. Landmark PFS was 59.2% (50.6–67.2) at 12 months and 41.5% (33.4–50.1) at 24 months. Estimates from the ALL dataset were directionally consistent but more heterogeneous. No statistically significant differences were detected between regimen families. Certainty of evidence was very low, mainly because of risk of bias and inconsistency. In cohorts using standardised outcome assessment, STZ-containing regimens were associated with objective responses in approximately one-third of patients, supporting their consideration when tumour shrinkage is a major therapeutic objective. These single-arm pooled estimates do not establish superiority among STZ schedules or relative to other treatments, and the PFS benchmarks require cautious interpretation because of substantial clinical and methodological heterogeneity.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Neuroendocrine TumorsPancreatic NeoplasmsStreptozocinHumans

Stichwörter der Autor:innen

advanced diseasechemotherapymeta-analysisobjective response ratepancreatic neuroendocrine tumoursprogression-free survivalstreptozotocin

Substanzen

Streptozocin

Autor:innen und Institutionen

  • Oncology Unit, Department of Clinical and Molecular Medicine, Sant'Andrea University Hospital, Sapienza University of Rome , Rome, Italy.
  • Department of Medical and Surgical Sciences and Translational Medicine, Faculty of Medicine and Psychology, PhD School in Translational Medicine and Oncology, Sapienza University of Rome , Rome, Italy.
  • Department of Medical and Surgical Sciences (DIMEC), Alma Mater Studiorum - University of Bologna , Bologna, Italy.
  • Department of Medical Oncology, GI and Neuroendocrine Tumours Unit, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, ENETS Center of Excellence , Milan, Italy.
  • U.O. Oncologia Medica 2 Universitaria - Azienda Ospedaliera Universitaria Pisana , Pisa, Italy.
  • Medical Oncology Unit, Comprehensive Cancer Center, Fondazione Policlinico Universitario Agostino Gemelli-IRCCS , Rome, Italy.

ORCID-Profile: Giuseppe Lamberti, Maria Grazia Maratta, Davide Campana

Zitieren

APA

Arrivi, G., Lamberti, G., Pusceddu, S., Marconcini, R., Maratta, M. G., Panzuto, F., & Campana, D. (2026). Streptozotocin-based chemotherapy in advanced PanNETs: a systematic review and meta-analysis. Endocrine-Related Cancer, 33(11). https://doi.org/10.1530/erc-26-0338

Vancouver

Arrivi G, Lamberti G, Pusceddu S, Marconcini R, Maratta MG, Panzuto F, et al. Streptozotocin-based chemotherapy in advanced PanNETs: a systematic review and meta-analysis. Endocrine-Related Cancer. 2026;33(11). doi:10.1530/erc-26-0338

BibTeX
@article{Arrivi2026,
  author = {Arrivi, Giulia and Lamberti, Giuseppe and Pusceddu, Sara and Marconcini, Riccardo and Maratta, Maria Grazia and Panzuto, Francesco and Campana, Davide},
  title = {Streptozotocin-based chemotherapy in advanced PanNETs: a systematic review and meta-analysis},
  journal = {Endocrine-Related Cancer},
  year = {2026},
  volume = {33},
  number = {11},
  doi = {10.1530/erc-26-0338}
}
Kostenlos starten →